HIM
SCLN

Hillsdale Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Hillsdale Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-27,800
Closed -$273K – 564
2015
Q2 		$273K Sell
27,800
-13,300
-32% -$121K 0.08% 287
2015
Q1 		$364K Hold
41,100
– – 0.09% 202
2014
Q4 		$360K Buy
+41,100
New +$333K 0.09% 181

Other funds holding SCLN

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return

Hillsdale Investment Management's SCLN Position: Q3 2015 in Review

Hillsdale Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2015, closing a stake of 27,800 shares — an estimated $273K sold.

Hillsdale Investment Management first reported a position in SCLN in Q4 2014 and held it in 3 quarters. The position peaked at $364K in Q1 2015. 134 funds tracked by Wall St. Rank hold SCLN as of Q3 2015.

  • Hillsdale Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Hillsdale Investment Management sold 27,800 Sciclone Pharmaceuticals Inc shares in Q3 2015, an estimated $273K.
  • Hillsdale Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 3 quarters.
  • Hillsdale Investment Management's Sciclone Pharmaceuticals Inc position peaked at $364K in Q1 2015.
  • 134 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2015.

Based on Hillsdale Investment Management's 13F filing for Q3 2015, filed 12 Nov 2015.